Silexan (Lavender Oil) for Anxiety: The Evidence

Most people know lavender as an aromatherapy scent used in candles and bath products. What most do not know is that an oral, standardized lavender oil preparation called Silexan has been through a rigorous clinical trial program, is approved in Germany as a prescription anxiolytic, and outperformed a benzodiazepine in a head-to-head trial. This is not the same as smelling lavender. This is pharmacology.

What is Silexan

Silexan is a proprietary, standardized lavender oil preparation made from Lavandula angustifolia. It contains approximately 36-38% linalool and 33-35% linalyl acetate as primary active constituents, with a defined terpene profile that distinguishes it from generic lavender essential oil. The oral capsule dose used in all clinical research is 80 mg.

It is critical to understand that topical or inhaled lavender and oral Silexan are different interventions. Aromatherapy studies on lavender show mild acute effects, largely through olfactory pathways. Silexan's effects are systemic—linalool and linalyl acetate reach the bloodstream after ingestion and act on receptors in the central nervous system through mechanisms not possible with aromatherapy.

Mechanisms of Action

Silexan's anxiolytic activity operates through several complementary pathways. First, linalool and linalyl acetate modulate GABA-A receptors as positive allosteric modulators—the same general mechanism as benzodiazepines, but at different receptor subunits and with different clinical effects (notably without the sedation and dependence of benzodiazepines).

Second, Silexan inhibits voltage-gated calcium channels in neurons. This is a mechanism shared with some anticonvulsant drugs (like gabapentin) and accounts for Silexan's ability to reduce neuronal excitability and anxious arousal without full sedation.

Third, Silexan has been shown to reduce serotonin reuptake to a mild degree in vitro, which may contribute to longer-term anxiolytic effects.

The net result is a broad-spectrum dampening of CNS excitability through multiple mechanisms—different enough from benzodiazepines to avoid dependence and sedation, similar enough in effect to produce clinically meaningful anxiolysis.

Clinical Trial Evidence

The clinical program for Silexan has produced five published RCTs, which is substantial for a botanical supplement.

The first pivotal trial (Woelk and Schlaefke, 2010) compared Silexan 80 mg/day to lorazepam 0.5 mg/day in patients with generalized anxiety disorder over 6 weeks. Both groups improved significantly and equivalently on the Hamilton Anxiety Scale (HAM-A). Silexan was non-inferior to the benzodiazepine without sedation, cognitive impairment, or dependence risk. This finding was significant enough to support its prescription approval in Germany.

A subsequent placebo-controlled trial in 221 patients with mixed anxiety disorder found Silexan 80 mg/day superior to placebo on HAM-A total score at 10 weeks, with no sedation compared to placebo.

A 2014 trial compared Silexan 80 mg/day to Silexan 160 mg/day and paroxetine 20 mg/day. All active treatments outperformed placebo. Silexan 160 mg showed greater anxiolytic effects than 80 mg.

A 2019 trial examining Silexan in patients with restlessness and disturbed sleep found significant improvements in sleep quality alongside anxiety reduction, making it potentially useful for the anxiety-insomnia combination common in GAD.

Dose and Practical Use

The clinically studied dose is 80 mg/day as a single capsule. Higher doses (160 mg/day) have been studied and show greater efficacy without additional side effects. Take with food.

Onset of effect is typically within 2 weeks, with maximum effects at 4-6 weeks. Unlike benzodiazepines, Silexan does not produce acute anxiolytic effects within minutes of a single dose—it works with daily consistent use.

Silexan is sold as a dietary supplement under various brand names in the US (look for products specifying linalool content and the 80 mg standardized lavender oil dose). It is sold as a prescription drug (Lasea) in Germany.

Safety Profile

The safety profile of Silexan is excellent. The most common side effect is mild eructation (burping with a lavender odor) due to the volatile oil nature of the compound. This occurs in approximately 10-15% of users and is not harmful. Taking with food or refrigerating capsules reduces this.

No sedation, no cognitive impairment, no dependence, and no significant drug interactions have been documented in clinical trials. It does not potentiate alcohol.

Silexan is not recommended in pregnancy or lactation due to insufficient safety data.

FAQ

Q: Can I just use lavender essential oil orally instead of Silexan?

No. Essential oils are not standardized, most are not intended for oral use, and the chemical composition differs. Ingesting random lavender essential oil can cause toxicity. Only specifically formulated oral lavender preparations should be taken orally.

Q: Does Silexan cause drowsiness?

At 80 mg, no. Clinical trials show Silexan does not differ from placebo on sedation measures. At higher doses, mild sedation can occur. This distinguishes it from most herbal anxiolytics (valerian, kava) which do cause sedation.

Q: How does Silexan compare to buspirone for GAD?

Both are non-sedating, non-dependent anxiolytics. Buspirone works via partial 5-HT1A agonism and takes 4-6 weeks to show effects—similar to Silexan. Direct head-to-head data does not exist, but both have similar evidence quality for GAD.

Q: Can I take Silexan with SSRIs?

No significant interaction is documented. Given its multi-modal mechanism, it may provide complementary benefits to SSRIs for residual anxiety symptoms. Disclose to your prescriber.

Track your supplements in Optimize.